- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06330623
Developing Personalised Relative Physical Activity Thresholds in COPD. (IMPACT)
Developing Personalised, Relative Intensity Physical Activity Thresholds for Accelerometer-Derived Measures of Physical Activity in COPD (IMPACT)
The aim of this observational study is to translate the principle of individualised exercise prescription into the evaluation of daily absolute and relative intensity physical activity.
The main questions this study aims to answer are:
- Phase 1: What does physical activity (intensity) mean to people with COPD?
- Phase 2: Are there differences between time spent in absolute and relative physical activity for people with COPD?
Phase 1 Participants will take part in semi-structured interview (30-45 minutes) about living with COPD and perceptions of physical activity and how they perceive intensity. This will also include photovoice and photo-elicitation. Demographic information will be recorded and participants will also complete several respiratory symptom questionnaires.
Phase 2:
Participants will take part in physical activity testing before and after pulmonary rehabilitation while wearing physical activity monitors. Demographic information will be recorded and participants will also complete several respiratory symptom and physical activity questionnaires. Participants will also wear the physical activity monitors for 8 days after the pre-testing sessions and after their final pulmonary rehabilitation class.
Sub-study:
Participants will be asked to take images of barriers during physical activity, facilitators during physical activity, feelings during physical activity and types of physical activity they take part in for 8 days after their final pulmonary rehabilitation class. Participants will then take part in a semi-structured interview about the images their have taken while doing physical activity.
Study Overview
Status
Conditions
Detailed Description
Physical activity (PA) helps prevent and manage non-communicable diseases such as chronic obstructive pulmonary disease (COPD). Pulmonary rehabilitation (PR) has been shown to benefit people living with COPD by reducing breathlessness, increasing muscle strength, and improving the management of exacerbations. However, the improvement in PA in individuals with COPD remains inconsistent following PR. Despite the personalised nature of PA prescription during PR, the evaluation of free-living PA data has been limited to a 'one size fits all' approach using absolute intensity categories. Reduced exercise tolerance can result in PA being perceived at a high intensity relative to a person's exercise capacity, despite the absolute intensity being low. Exploring both the relative and absolute intensity of PA could offer additional insights and clinical relevance for the evaluation of physical activity in COPD populations.
The aim of this research is to translate the principle of individualised exercise prescription into the evaluation of daily absolute and relative intensity PA in a user-friendly format for PR teams and service users.
Phase 1 objective: To explore what PA means to people with COPD in the context of relative intensity and pulmonary rehabilitation.
Phase 2 objective: To examine the differences between time spent in physical activity intensity expressed in absolute and relative terms for people with COPD.
Phase 1: Semi-structured interviews will take place where participants will discuss their COPD and their perceptions of physical activity and relative intensity. The interviews will be in person (Biomedical research centre, Leicester) or over the phone/video call. The participants will complete several questionnaires about respiratory symptoms. Before taking part in the interviews, participants will also be asked to take pictures, using a camera provided, of when they are doing physical activity. This will be for a 7 day period before the interview.
Phase 2: Participants will take part in exercise testing and complete questionnaires pre and post pulmonary rehabilitation while wearing activity and gait monitors. Participants will also be asked to wear the activity monitors for 8-days after the pre-testing sessions and 8-days after their last pulmonary rehabilitation class. Following their last pulmonary rehabilitation class, 20 participants will be asked to take photographs during the period they are wearing accelerometers and motion sensors. When the participants return the devices, they will take part in an interview to discuss the images they have taken while taking part in physical activity.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Leicestershire
-
Leicester, Leicestershire, United Kingdom, LE67 2DU
- NIHR Leicester Biomedical Research Centre - Respiratory
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Phase 1:
Patients from the COPD nursing ward, previous research studies and pulmonary rehabilitation programme.
Phase 2:
Patients from the pulmonary rehabilitation programme.
Description
Phase 1:
Inclusion Criteria:
- Willing and able to provide informed consent for participation in the research.
- The patient has a confirmed diagnosis of COPD using spirometry (based on GOLD criteria (Agustí et al., 2023).
- Male or female, aged 40+ years
- Able to communicate in written and spoken English.
Exclusion Criteria:
- Unable to provide valid informed consent.
- Severe psychiatric disorders
- Aged less than 40 years
- Unable to understand written or spoken English.
Phase 2:
Inclusion Criteria:
- Willing and able to provide informed consent for participation in the research.
- The patient has a confirmed diagnosis of COPD using spirometry (based on GOLD criteria.
- The patient is referred for PR at the UHL.
- Male or female, aged 40+ years
- Able to communicate in written and spoken English
Exclusion Criteria:
- Unable to provide valid informed consent.
- Lack of motivation to participate in PR programme.
- Any-contra-indications absolute or relative to exercise training.
- Has had a cardiac event within last 6 weeks
- Severe psychiatric disorders
- Patients with a history of MRSA +ve screens (patients can be assessed and given an exercise programme but cannot attend the classes. Patients need to have 3 consecutive -ve MRSA swabs before they can attend).
- Aged less than 40 years
- Unable to understand written or spoken English.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Phase 1 Cohort
These participants will be recruited from:
|
|
Phase 2 Cohort
These participants will be recruited from the pulmonary rehabilitation service.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phase 1 - Semi-structured Interviews
Time Frame: 30-45 minutes
|
Semi-structured interview with individuals with COPD
|
30-45 minutes
|
|
Phase 2 - Differences between time spent in PA intensity expressed in absolute and relative intensity.
Time Frame: 8 days
|
Differences between time spent in PA intensity expressed in absolute and relative using activity monitors (wrist and waist) for eight days before and after the PR programme.
|
8 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phase 1 - Medical Research Council (MRC) Dyspnoea Scale
Time Frame: 2 minutes
|
Medical Research Council (MRC) Dyspnoea Scale Minimum value: 1 Maximum value: 5 The higher the score, the worse the outcome (breathlessness).
|
2 minutes
|
|
Phase 1 - COPD Assessment Test (CAT)
Time Frame: 5 minutes
|
COPD Assessment Test (CAT)
|
5 minutes
|
|
Phase 1 - Chronic Respiratory Questionnaire (CRQ-SR)
Time Frame: 5 minutes
|
Chronic Respiratory Questionnaire (CRQ-SR)
|
5 minutes
|
|
Phase 1 - Photovoice and photo-elicitation
Time Frame: 7 days
|
Photovoice is a qualitative research method that focuses on participants identifying and addressing important topics that matter to them through photography.
This will gain greater insight from the participants about their experiences of participating in PA.
Participant-generated images will be used to inform the photo-elicitation aspect of the interview to enable participants to capture in real time, more graphically illustrate their experiences and perceptions of different types of PA.
|
7 days
|
|
Phase 2 - Medical Research Council (MRC) Dyspnoea Scale
Time Frame: 2 minutes
|
Medical Research Council (MRC) Dyspnoea Scale
|
2 minutes
|
|
Phase 2 - COPD Assessment Test (CAT)
Time Frame: 5 minutes
|
COPD Assessment Test (CAT)
|
5 minutes
|
|
Phase 2 - Chronic Respiratory Questionnaire (CRQ-SR)
Time Frame: 5 minutes
|
Chronic Respiratory Questionnaire (CRQ-SR)
|
5 minutes
|
|
Phase 2 - Gait Analysis
Time Frame: 45 minutes
|
Gait Analysis - Speed, Variability, Asymmetry
|
45 minutes
|
|
Phase 2 - Exercise Capacity (ISWT)
Time Frame: 30-45 minutes
|
Incremental Shuttle Walk Test
|
30-45 minutes
|
|
Phase 2 - Exercise Capacity (ESWT)
Time Frame: 15-30 minutes
|
Endurance Shuttle Walk Test
|
15-30 minutes
|
|
Phase 2 - Photovoice and photo-elicitation
Time Frame: 8 days
|
Photovoice is a qualitative research method that focuses on participants identifying and addressing important topics that matter to them through photography.
This will gain greater insight from the participants about their experiences of participating in PA.
Participant-generated images will be used to inform the photo-elicitation aspect of the interview to enable participants to capture in real time, more graphically illustrate their experiences and perceptions of different types of PA.
|
8 days
|
|
Phase 2 - Clinical PROactive Physical Activity instrument in COPD (C-PPAC)
Time Frame: 5 minutes
|
Clinical PROactive Physical Activity instrument in COPD (C-PPAC)
|
5 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: University of Leicester University of Leicester, University of Leicester
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0929
- 321985 (Other Identifier: HRA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
University of LeicesterUniversity Hospitals, Leicester; University of StrathclydeRecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway DiseaseUnited Kingdom
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
Strados Labs, Inc.WithdrawnChronic Obstructive Pulmonary Disease (COPD)United States
-
Pulmatrix Inc.CompletedChronic Obstructive Pulmonary Disease (COPD)United Kingdom
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease (COPD)United States